Genenta Science S.p.A. (NASDAQ: GNTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Genenta Science S.p.A. - American Depositary Shares (GNTA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
GNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNTA alerts
High impacting Genenta Science S.p.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GNTA
News
- Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”GlobeNewswire
- Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders [Yahoo! Finance]Yahoo! Finance
- Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell CancerGlobeNewswire
GNTA
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 424B5
- 12/13/24 - Form 6-K
- GNTA's page on the SEC website